NewKerala.com

Nadda Reviews IPC Progress, Lauds India's Global Pharmacy Leadership

Union Health Minister J P Nadda reviewed the progress of the Indian Pharmacopoeia Commission, commending its role in ensuring medicine quality and public health safety. He highlighted that the Indian Pharmacopoeia is now recognized in 19 countries, bolstering India's reputation as the "Pharmacy of the World." The 10th edition of the Indian Pharmacopoeia is scheduled for launch in January 2026. Nadda also emphasized IPC's crucial work in pharmacovigilance and encouraged continued innovation and global harmonization of standards.

Key Points: Nadda Reviews Indian Pharmacopoeia Commission's Progress & Global Role

  • IPC strengthens drug standards & safety
  • Indian Pharmacopoeia recognized globally
  • 10th edition launching in 2026
  • Key to Atmanirbhar & Viksit Bharat vision
2 min read

J P Nadda reviews progress and initiatives of Indian Pharmacopoeia Commission

Union Health Minister J P Nadda reviewed IPC initiatives, highlighting global recognition in 19 countries and the upcoming 10th edition of the Indian Pharmacopoeia 2026.

"the Indian Pharmacopoeia is now recognised in 19 countries, reflecting growing international confidence in India's regulatory and scientific capabilities. - J P Nadda"

New Delhi, December 26

Union Minister of Health and Family Welfare, Jagat Prakash Nadda today reviewed the progress and initiatives of the Indian Pharmacopoeia Commission in the presence of Nivedita Shukla Verma, Secretary, Department of Chemicals and Petrochemicals, who also holds the additional charge as Secretary, MoHFW.

According to the Ministry of Health and Family Welfare, Nadda appreciated IPC's sustained efforts in strengthening pharmacopoeial standards and pharmacovigilance activities, which contribute to the Government's vision of Atmanirbhar Bharat and a Viksit Bharat, promoting self-reliance, scientific excellence, and robust healthcare standards.

During the review, JP Nadda commended IPC for its pivotal role in ensuring the quality, safety, and efficacy of medicines, thereby protecting public health. He noted that the Indian Pharmacopoeia remains a critical scientific and regulatory reference, ensuring uniform standards of medicines across the country.

The Minister highlighted that "the Indian Pharmacopoeia is now recognised in 19 countries, reflecting growing international confidence in India's regulatory and scientific capabilities." He observed that "this recognition strengthens India's position as the Pharmacy of the World and underscores the credibility of Indian pharmacopoeial standards globally."

In addition to this, the 10th edition of the Indian Pharmacopoeia 2026 is scheduled to be launched by the Union Health Minister in the first week of January 2026.

In the meeting, Shri Nadda emphasised IPC's crucial role in implementing the Pharmacovigilance Programme of India (PvPI) to monitor adverse drug reactions and ensure patient safety and appreciated its efforts to strengthen reporting systems and build capacity among healthcare professionals. He also lauded IPC's contribution to Atmanirbhar Bharat through strengthening indigenous scientific expertise and regulatory standards while supporting global public health.

The Minister encouraged IPC to continue to focus on innovation, digitalisation, and global harmonisation of standards, in line with the vision of Viksit Bharat, to ensure universal access to safe, high-quality medicines.

The details of the activities were presented by Dr V Kalaiselvan, Secretary-cum-Scientific Director (IPC) and he further reaffirmed the commitment to strengthen pharmacopoeial and pharmacovigilance standards further, enhancing international collaboration and contributing to national and global health objectives.

Harsh Mangla, Joint Secretary, MoHFW and other senior officers of the Ministry were also present at the meeting.

- ANI

Share this article:

Reader Comments

P
Priyanka N
Very encouraging news. The focus on pharmacovigilance (PvPI) is especially important. We need robust systems to monitor drug safety. As a common citizen, it gives me confidence that the government is actively working to ensure the medicines we buy are safe and effective. Hope the 2026 edition brings even more stringent standards.
R
Rahul R
While the international recognition is good, I hope this translates to better quality control on the ground. We still hear about sub-standard drugs in some markets. The standards are great, but their uniform implementation across all manufacturers, big and small, is the real challenge. The IPC's work will only matter if enforcement is strict.
S
Sarah B
As someone who works in global health, this is significant. Harmonizing Indian pharmacopoeial standards with global ones reduces trade barriers and builds trust. It's a smart move for both public health and the economy. The digitalization push mentioned is also key for modern healthcare systems.
K
Karthik V
Atmanirbhar Bharat in action! Strengthening our own scientific and regulatory capabilities means we rely less on foreign standards and can export with confidence. This supports our pharmaceutical industry and creates jobs. Good step towards a Viksit Bharat. Jai Hind!
M
Meera T
The patient safety angle is most important. Monitoring adverse drug reactions can save lives. I'm glad they're building capacity among healthcare professionals for this. Doctors and pharmacists need to be vigilant and report issues. This is a core part of a reliable healthcare system.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50